$FCHS
First Choice Healthcare Solutions Inc Stock $fchs

$fchs Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-K Financial Statement

#000114420415022784 Filed on April 15, 2015

Income Statement

Concept	2014 Q4	2014	2013 Q4
Revenue	$1.870M	$8.103M	$1.620M
YoY Change	15.43%	672.8%	33.88%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.490M	$2.434M	$1.900M
YoY Change	31.05%	42.76%	216.67%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$140.0K	$552.1K	$150.0K
YoY Change	-6.67%	6.45%	25.0%
% of Gross Profit
Operating Expenses	$3.260M	$9.646M	$2.430M
YoY Change	34.16%	35.45%	88.37%
Operating Profit		-$1.543M
YoY Change		57.76%
Interest Expense	-$240.0K	-$866.7K	-$2.880M
YoY Change	-91.67%	-123.4%	1271.43%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$946.4K	$0.00
YoY Change		-74.6%
Pretax Income	-$1.630M	-$2.490M	-$4.150M
YoY Change	-60.72%	-47.08%	1382.14%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.630M	-$2.490M	-$4.150M
YoY Change	-60.72%	-47.08%	1382.14%
Net Earnings / Revenue	-87.17%	-30.73%	-256.17%
Basic Earnings Per Share		-$0.14
Diluted Earnings Per Share	-$0.09	-$0.14	-$0.27
COMMON SHARES
Basic Shares Outstanding	17.71M shares	17.25M shares
Diluted Shares Outstanding		17.25M shares

Balance Sheet

Concept	2014 Q4	2014	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$280.0K	$279.1K	$740.0K
YoY Change	-62.16%	-62.24%	957.14%
Cash & Equivalents	$279.1K		$739.2K
Short-Term Investments
Other Short-Term Assets	$540.0K	$539.9K	$450.0K
YoY Change	20.0%	18.88%	28.57%
Inventory
Prepaid Expenses
Receivables	$1.805M	$1.805M	$1.272M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.624M	$2.624M	$2.465M
YoY Change	6.42%	6.41%	161.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.294M	$8.294M	$8.662M
YoY Change	-4.25%	-4.25%	-1.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$552.7K	$40.35K	$685.8K
YoY Change	-19.4%	-69.94%	59.02%
Total Long-Term Assets	$8.847M	$8.847M	$9.348M
YoY Change	-5.36%	-5.36%	1.74%
TOTAL ASSETS
Total Short-Term Assets	$2.624M	$2.624M	$2.465M
Total Long-Term Assets	$8.847M	$8.847M	$9.348M
Total Assets	$11.47M	$11.47M	$11.81M
YoY Change	-2.9%	-2.9%	16.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.460M	$1.457M	$460.0K
YoY Change	217.39%	217.49%	-20.69%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$220.0K	$224.0K	$0.00
YoY Change
Long-Term Debt Due	$4.120M	$4.119M	$1.540M
YoY Change	167.53%	166.79%	49.51%
Total Short-Term Liabilities	$6.376M	$6.376M	$2.244M
YoY Change	184.15%	184.15%	36.02%
LONG-TERM LIABILITIES
Long-Term Debt	$8.257M	$8.185M	$11.36M
YoY Change	-27.28%	-27.46%	16.08%
Other Long-Term Liabilities	$70.00K	$72.90K	$70.00K
YoY Change	0.0%	0.0%	-68.18%
Total Long-Term Liabilities	$8.257M	$8.257M	$11.36M
YoY Change	-27.28%	-27.28%	16.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.376M	$6.376M	$2.244M
Total Long-Term Liabilities	$8.257M	$8.257M	$11.36M
Total Liabilities	$14.63M	$14.63M	$13.60M
YoY Change	7.6%	7.6%	18.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$15.85M		-$13.36M
YoY Change	18.63%		54.33%
Common Stock	$17.95K		$16.75K
YoY Change	7.19%		31.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.163M	-$3.163M	-$1.787M
YoY Change
Total Liabilities & Shareholders Equity	$11.47M	$11.47M	$11.81M
YoY Change	-2.9%	-2.9%	16.6%

Cashflow Statement

Concept	2014 Q4	2014	2013 Q4
OPERATING ACTIVITIES
Net Income	-$1.630M	-$2.490M	-$4.150M
YoY Change	-60.72%	-47.08%	1382.14%
Depreciation, Depletion And Amortization	$140.0K	$552.1K	$150.0K
YoY Change	-6.67%	6.45%	25.0%
Cash From Operating Activities	$130.0K	-$363.9K	-$920.0K
YoY Change	-114.13%	-71.21%	1214.29%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$145.2K	$80.00K
YoY Change	-100.0%	-63.48%	-73.33%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$20.00K
YoY Change	-100.0%	-100.0%	100.0%
Cash From Investing Activities	$0.00	-$145.2K	-$60.00K
YoY Change	-100.0%	-60.98%	-78.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.00K	49.09K	1.530M
YoY Change	-98.69%	-97.87%	595.45%
NET CHANGE
Cash From Operating Activities	130.0K	-363.9K	-920.0K
Cash From Investing Activities	0.000	-145.2K	-60.00K
Cash From Financing Activities	20.00K	49.09K	1.530M
Net Change In Cash	150.0K	-460.1K	550.0K
YoY Change	-72.73%	-168.45%	-523.08%
FREE CASH FLOW
Cash From Operating Activities	$130.0K	-$363.9K	-$920.0K
Capital Expenditures	$0.00	$145.2K	$80.00K
Free Cash Flow	$130.0K	-$509.2K	-$1.000M
YoY Change	-113.0%	-69.36%	170.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	739158	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	279087	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	256246	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2244061	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6376414	USD
CY2013Q4	us-gaap	Customer Deposits Noncurrent CustomerDepositsNoncurrent	72901	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	732791	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	First Choice Healthcare Solutions, Inc.
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001416876
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q2	dei	Entity Public Float EntityPublicFloat	18312622	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	74934	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	38763	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	318259	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1272155	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1804636	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	140580	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	153296	USD
CY2013Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	57348	USD
CY2014Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	68370	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	2465487	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	2623648	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8662057	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8294298	USD
CY2013Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	131540	USD
CY2014Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	37775	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	265000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	245000	USD
CY2013Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	286500	USD
CY2014Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	267400	USD
CY2013Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2713	USD
CY2014Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2571	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	685753	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	552746	USD
CY2013Q4	us-gaap	Assets Assets	11813297	USD
CY2014Q4	us-gaap	Assets Assets	11470692	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	459000	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1457275	USD
CY2013Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	166340	USD
CY2014Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	537750	USD
CY2013Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	800000	USD
CY2014Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1237000	USD
CY2013Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2014Q4	us-gaap	Customer Deposits Noncurrent CustomerDepositsNoncurrent	72901	USD
CY2014Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2148835	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent	743787	USD
CY2013Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2347403	USD
CY2014Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	8935473	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	8184560	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11355777	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8257461	USD
CY2013Q4	us-gaap	Liabilities Liabilities	13599838	USD
CY2014Q4	us-gaap	Liabilities Liabilities	14633875	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	16747	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	17951	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11560249	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12671942	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13363537	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15853076	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-1786541	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-3163183	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11813297	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11470692	USD
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, and stock-based compensation. Actual results may differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Concentrations of Credit Risk</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable.  Occasionally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	7642507	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	523316	USD
CY2014Q4	us-gaap	Notes Payable NotesPayable	8917351	USD
CY2014	us-gaap	Property Plant And Equipment Depreciation Methods PropertyPlantAndEquipmentDepreciationMethods	straight-line method
CY2013Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	148626	USD
CY2014Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	231369	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	361284	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1482212	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3414070	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3751502	shares
CY2013	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1238480	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10766409	USD
CY2013	us-gaap	Depreciation Depreciation	483797	USD
CY2014	us-gaap	Depreciation Depreciation	512984	USD
CY2013	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2016-12-31
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1959127	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2472111	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	35000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	55000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16747248	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17951055	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16747248	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17951055	shares
CY2013Q4	us-gaap	Notes Payable NotesPayable	9679260	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	35098	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	18737	USD
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	8917351	USD
CY2013	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	5094358	USD
CY2014	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	7053603	USD
CY2013	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	1048469	USD
CY2013	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	6142827	USD
CY2014	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	8102602	USD
CY2013	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3096285	USD
CY2013	us-gaap	Other General Expense OtherGeneralExpense	1350927	USD
CY2014	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2014	us-gaap	Labor And Related Expense LaborAndRelatedExpense	4761573	USD
CY2014	us-gaap	Other General Expense OtherGeneralExpense	1897780	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1750154	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2434259	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	518611	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	552084	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	7120977	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	9645696	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-978150	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-1543094	USD
CY2013	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-3704086	USD
CY2014	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-866701	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3063	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4704303	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2489539	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-4704303	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-2489539	USD
CY2013	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	5459373	USD
CY2014	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	7966385	USD
CY2013	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	365015	USD
CY2014	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	912782	USD
CY2014	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	1048999	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1705154	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2434259	USD
CY2013	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	32218	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	57348	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	82744	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3726153	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-946445	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13529294	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17249921	shares
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-1301534	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	383101	USD
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	626340	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	624000	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	150000	USD
CY2013	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	96000	USD
CY2014	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	518611	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	552084	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2706869	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	361284	USD
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	912782	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	549441	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	997750	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1105572	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1445263	USD
CY2013	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	70604	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	62013	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-91312	USD
CY2014	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	12574	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1136264	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	35496	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-36171	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1264058	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-363937	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	397688	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	145225	USD
CY2013	us-gaap	Increase Decrease In Other Deposits IncreaseDecreaseInOtherDeposits	25502	USD
CY2014	us-gaap	Increase Decrease In Other Deposits IncreaseDecreaseInOtherDeposits	0	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-372186	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-145225	USD
CY2013	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-10846	USD
CY2014	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2128117	USD
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2013	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1373208	USD
CY2014	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	587000	USD
CY2013	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	152659	USD
CY2014	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2013	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1334781	USD
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	761909	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2308357	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	49091	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	672113	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-460071	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67045	USD
CY2013	us-gaap	Interest Paid InterestPaid	731877	USD
CY2014	us-gaap	Interest Paid InterestPaid	783958	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013Q4	us-gaap	Customer Advances Current CustomerAdvancesCurrent	0	USD
CY2014Q4	us-gaap	Customer Advances Current CustomerAdvancesCurrent	224000	USD
CY2013	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	286500	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2013	fchs	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Value Of Shares Issued NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfSharesIssued	450000	USD
CY2014	fchs	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Value Of Shares Issued NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfSharesIssued	0	USD
CY2013	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	224000	USD
CY2013	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	397688	USD
CY2014	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	145225	USD
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18432055	shares
CY2014	dei	Trading Symbol TradingSymbol	FCHS
CY2013	fchs	Stock Issued During Period Value Conversion Of Related Party Convertible Debt StockIssuedDuringPeriodValueConversionOfRelatedPartyConvertibleDebt	142484	USD
CY2013	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	450000	USD
CY2013	fchs	Common Stock Issued For Subscription CommonStockIssuedForSubscription	0	USD
CY2013	fchs	Adjustments To Additional Paid In Capital Reclassification Of Derivative Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityToEquity	366094	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1871117	USD
CY2013	us-gaap	Costmethod Investments Other Than Temporary Impairment CostmethodInvestmentsOtherThanTemporaryImpairment	450000	USD
CY2013	fchs	Stockissued For Loan Modification StockissuedForLoanModification	-96000	USD
CY2014	fchs	Stockissued For Loan Modification StockissuedForLoanModification	0	USD
CY2013	fchs	Stock Issued For Related Party Line Of Credit StockIssuedForRelatedPartyLineOfCredit	142484	USD
CY2014	fchs	Stock Issued For Related Party Line Of Credit StockIssuedForRelatedPartyLineOfCredit	0	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	0	USD
CY2014	fchs	Adjustments To Additional Paid In Capital Reclassification Of Derivative Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeLiabilityToEquity	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	490000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	210000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	490000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	210000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.036	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.350	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.386	pure
CY2014Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5410000	USD
CY2014	fchs	Cost Method Investments Other Than Temporary Impairment Per Share CostMethodInvestmentsOtherThanTemporaryImpairmentPerShare	0.03
CY2014Q4	us-gaap	Cost Method Investments CostMethodInvestments	0	USD
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13529294	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17249921	shares
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13529294	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17249921	shares
CY2013Q4	us-gaap	Cost Method Investments CostMethodInvestments	0	USD
CY2013	fchs	Cost Method Investments Other Than Temporary Impairment Per Share CostMethodInvestmentsOtherThanTemporaryImpairmentPerShare	0.03
CY2014Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	16835	USD
CY2014Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	0	USD
CY2014Q4	fchs	Contractual Obligation Total ContractualObligationTotal	16835	USD
CY2014	us-gaap	Costmethod Investments Other Than Temporary Impairment CostmethodInvestmentsOtherThanTemporaryImpairment	0	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	732791	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		USD
CY2013	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	0	USD
CY2014	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	0	USD
CY2013	us-gaap	Impairment Of Investments ImpairmentOfInvestments	450000	USD
CY2013	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	286500	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1432	USD
CY2014	us-gaap	Stock Issued During Period Shares Issued For Noncash Consideration StockIssuedDuringPeriodSharesIssuedForNoncashConsideration	30000	shares
CY2014Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.08	pure
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	100000	shares
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	98000	USD
CY2014Q3	us-gaap	Loss Contingency Receivable LossContingencyReceivable	2000000	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	336557	USD

Files In Submission

Name	View Source	Status
0001144204-15-022784-index-headers.html	Edgar Link	pending
0001144204-15-022784-index.html	Edgar Link	pending
0001144204-15-022784.txt	Edgar Link	pending
0001144204-15-022784-xbrl.zip	Edgar Link	pending
fchs-20141231.xml	Edgar Link	completed
fchs-20141231.xsd	Edgar Link	pending
fchs-20141231_cal.xml	Edgar Link	unprocessable
fchs-20141231_def.xml	Edgar Link	unprocessable
fchs-20141231_lab.xml	Edgar Link	unprocessable
fchs-20141231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpg6.jpg	Edgar Link	pending
v404949_10k.htm	Edgar Link	pending
v404949_ex31-1.htm	Edgar Link	pending
v404949_ex31-2.htm	Edgar Link	pending
v404949_ex32-1.htm	Edgar Link	pending
v404949_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FCHS
First Choice Healthcare Solutions Inc Stock $fchs

2014 Q4 Form 10-K Financial Statement

#000114420415022784 Filed on April 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FCHS First Choice Healthcare Solutions Inc Stock $fchs

2014 Q4 Form 10-K Financial Statement

#000114420415022784 Filed on April 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FCHS
First Choice Healthcare Solutions Inc Stock $fchs